Ascentage Pharma Group International: Trustee Purchases Shares for 2022 RSU Scheme
Key Developments and Implications for Investors
Ascentage Pharma Group International (Stock Code: 6855) has voluntarily announced that, on May 27, 2026, the trustee appointed under its 2022 Restricted Share Unit (RSU) Scheme purchased 100,000 existing shares on the open market. This move is aimed at satisfying the vesting of RSUs previously granted under the scheme.
Key Points from the Announcement
- Purchase Date: May 27, 2026
- Total Shares Purchased: 100,000 (approximately 0.0268% of the company’s issued shares)
- Total Consideration: HK\$3,977,000 (excluding transaction costs)
- Average Purchase Price: Approximately HK\$39.77 per share
- Total Shares Held by Trustee for the RSU Scheme (post-purchase): 2,265,000 shares
- Shares Held by Trustee: Shares are held in accordance with the RSU Scheme rules, and the trustee does not exercise voting rights for these shares.
Background and Context
This purchase forms part of the company’s ongoing efforts to satisfy awards under the 2022 RSU Scheme. The scheme was initially adopted and amended at various points, with initial and subsequent RSU grants made on June 23, 2022; May 4, 2023; September 2, 2024; June 27, 2025; November 26, 2025; and April 20, 2026. No further grants have been made beyond these dates.
The shares acquired by the trustee will be used to fulfill RSU vesting obligations, ensuring the company can deliver shares to eligible participants as their awards vest.
Potential Impact on Shareholders and Share Price
- Buyback Activity: The on-market purchase of shares by the trustee could offer support to the share price, as it reduces the free float and signals confidence in the company’s share value.
- Share Dilution: Since the shares are purchased from the open market rather than issued as new shares, there is no dilution effect for existing shareholders.
- Governance Note: The trustee does not exercise voting rights on these shares, maintaining the current balance of power among shareholders.
- Transparency: The company’s detailed disclosure of RSU grants and purchases enhances corporate transparency, which may be viewed positively by investors.
Board and Corporate Governance
The Board is led by Dr. Yang Dajun (Chairman and Executive Director), with two non-executive directors (Dr. Wang Shaomeng and Dr. Lu Simon Dazhong), and six independent non-executive directors, including Dr. David Sidransky (Lead Independent Director). Notably, Dr. Lu Simon Dazhong meets U.S. SEC and Nasdaq independence requirements, which may be important to international investors.
Conclusion
The recent purchase of shares by the trustee for the RSU Scheme is a routine but positive action, supporting the company’s incentive structure without diluting shareholder value. While not a major event, it does demonstrate ongoing commitment to staff retention and alignment of interests with shareholders, which can be price supportive in the current market environment.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a professional advisor before making investment decisions.
亞盛醫藥集團國際：受託人為2022年RSU計劃購入股份
重點發展及對投資者的啟示
亞盛醫藥集團國際（股份代號：6855）自願宣布，於2026年5月27日，根據2022年限制性股份單位（RSU）計劃的受託人於公開市場購入100,000股現有股份，用以滿足早前授出的RSU歸屬安排。
公告要點
- 購入日期：2026年5月27日
- 購入股份總數：100,000股（約佔公司已發行股份總數0.0268%）
- 購入總對價：港幣3,977,000元（不含交易費用）
- 每股平均購入價：約港幣39.77元
- 受託人現持RSU股份（購入後）：2,265,000股
- 股份持有安排：股份根據RSU計劃規則持有，受託人不行使持有股份的投票權。
背景及情況說明
今次購入屬於公司根據2022年RSU計劃履行股份獎勵承諾的持續行動。該計劃於多個日子獲採納和修訂，歷次RSU授出日包括2022年6月23日、2023年5月4日、2024年9月2日、2025年6月27日、2025年11月26日及2026年4月20日，除上述外暫未有進一步授出。
所購入股份將用於履行RSU歸屬，確保公司可於獎勵歸屬時向合資格人士交付股份。
對股東及股價的潛在影響
- 股份回購行動： 受託人在市場購入股份，有助於支持股價，減少市場流通股份，亦展現對公司價值的信心。
- 無攤薄效應： 由於股份為市場購入而非新發行，對現有股東並無攤薄影響。
- 公司管治： 受託人不行使投票權，維持股東權益平衡。
- 資訊透明： 公司詳細披露RSU授出及股份購入，有助提升企業管治透明度，對投資者屬正面訊號。
董事會及公司管治
董事會由楊大俊博士（主席兼執行董事）領導，非執行董事包括王少萌博士和盧大中博士，另有六名獨立非執行董事，包括首席獨立董事David Sidransky博士。值得注意的是，盧大中博士符合美國SEC及納斯達克獨立性要求，這對國際投資者尤為重要。
總結
今次受託人購入股份屬於公司員工激勵計劃的例行安排，有助員工留任及與股東利益保持一致，對公司股價有潛在正面支持作用，亦無攤薄現有股東權益。
免責聲明
本文僅供參考，並不構成任何投資建議。投資者應自行研究或諮詢專業顧問，方作投資決定。
